ARTEL Holds Industry's First Multichannel Pipetting Technique Certification Seminar
ARTEL Holds Industry's First Multichannel Pipetting Technique Certification Seminar
WESTBROOK, ME, July 10, 2007-To help laboratories improve pipetting technique and reduce laboratory error, ARTEL held a Pipetting Proficiency Training and Certification Seminar, including the industry’s first certification for multichannel pipetting technique. All participants succeeded in measurably improving the repeatability of their pipetting. Twenty-seven technicians from biopharmaceutical, clinical and university laboratories attended.
Operator technique is a major source of pipetting error and inaccurate data, especially during use of multichannel pipettes. Compared to single-channel pipettes, multichannel devices are more prone to mechanical and operator error. Technique problems common to multichannel pipettes include incorrect rocking motions or excessive force when mounting tips, and the hand-warming that results when fingers are used to tighten tips. These and other critical issues were addressed during the training.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
